Department of Maternal and Child Health, School of Public Health, Peking University, Beijing, 100191, P. R. China.
National Center for Women and Children's Health, Chinese Center for Disease Control and Prevention, Beijing, 100081, P. R. China.
Cancer Commun (Lond). 2022 Mar;42(3):191-204. doi: 10.1002/cac2.12256. Epub 2022 Feb 10.
Primary human papillomavirus (HPV) screening is recommended for the detection of cervical intraepithelial neoplasia (CIN) in the general population; however, the triage for HPV-positive women remains a challenge. This study aimed to evaluate the age-specific effectiveness of primary HPV screening versus primary cytology screening for identifying optimal strategies for women of different ages.
The dataset of the prevalence round screening was derived from the National Cervical Cancer Screening Program in China. Primary cervical screening protocols included cytology only, HPV testing with cytology triage, and HPV testing with HPV-16/18 genotyping plus cytology triage. The primary outcomes were age-specific detection rate, colposcopy referral rate and positive predictive value (PPV) for CIN2+. Multivariate Poisson regression was used to evaluate the relative effectiveness of HPV testing and cytology according to age groups. The I statistic with a random-effect model was used to test the heterogeneity in relative effectiveness of HPV testing versus cytology between age groups.
This study included 1,160,981 women. HPV testing with HPV-16/18 genotyping plus cytology triage significantly increased the CIN2+ detection by 36% (rate ratio [RR]: 1.36, 95% confidential interval [CI] 1.21-1.54) for women aged 35-44 years and by 34% (RR: 1.34, 95% CI 1.20-1.51) for women aged 45-54 years compared with cytology only. HPV testing with cytology triage had similar CIN2+ detection rate compared with cytology only. The PPVs were substantially increased for both HPV testing groups. Among women aged 55-64 years old, HPV testing with HPV-16/18 genotyping plus cytology triage increased the colposcopy referral rate by 19% (RR 1.19, 95% CI 1.10-1.29) compared with cytology only, but did not increase the CIN2+ detection (1.09, 0.91-1.30). The effectiveness of HPV testing with cytology triage did not change in older women. The between-age-group heterogeneity in the effectiveness was statistically significant for HPV testing with HPV-16/18 genotyping plus cytology triage versus cytology only.
Our results suggested that the effectiveness of primary HPV screening with different triage strategies differed among age groups. HPV testing with HPV-16/18 genotyping plus cytology triage could be used for women aged 35-54 years to detect more lesions, and HPV testing with cytology triage could balance the CIN2+ detection and the number of colposcopies for women aged 55-64 years. Longitudinal data including both prevalence and incidence screening rounds are warranted to assess age-specific triage strategies.
原发性人乳头瘤病毒(HPV)筛查被推荐用于检测普通人群的宫颈上皮内瘤变(CIN);然而,HPV 阳性女性的分流仍然是一个挑战。本研究旨在评估原发性 HPV 筛查与原发性细胞学筛查对不同年龄女性的最佳策略。
本研究的数据来自中国国家宫颈癌筛查计划的患病率轮次筛查。初级宫颈筛查方案包括仅细胞学检查、HPV 检测伴细胞学分流以及 HPV 检测伴 HPV-16/18 基因分型加细胞学分流。主要结局是年龄特异性检出率、阴道镜转诊率和 CIN2+的阳性预测值(PPV)。采用多变量泊松回归根据年龄组评估 HPV 检测和细胞学的相对效果。采用随机效应模型的 I 统计量检验 HPV 检测与细胞学在年龄组之间的相对效果的异质性。
本研究纳入了 1160981 名女性。HPV 检测伴 HPV-16/18 基因分型加细胞学分流显著增加了 35-44 岁女性的 CIN2+检出率(RR:1.36,95%置信区间[CI]:1.21-1.54)和 45-54 岁女性的 CIN2+检出率(RR:1.34,95%CI:1.20-1.51),与仅细胞学检查相比。HPV 检测伴细胞学分流与仅细胞学检查的 CIN2+检出率相似。两种 HPV 检测组的 PPV 均显著增加。对于 55-64 岁的女性,HPV 检测伴 HPV-16/18 基因分型加细胞学分流使阴道镜转诊率增加了 19%(RR 1.19,95%CI:1.10-1.29),与仅细胞学检查相比,但并未增加 CIN2+的检出率(1.09,95%CI:0.91-1.30)。在年龄较大的女性中,HPV 检测伴细胞学分流的效果没有改变。HPV 检测伴 HPV-16/18 基因分型加细胞学分流与仅细胞学检查相比,在不同年龄组之间的效果存在统计学显著差异。
我们的结果表明,不同分流策略的原发性 HPV 筛查的效果在不同年龄组之间存在差异。HPV 检测伴 HPV-16/18 基因分型加细胞学分流可用于 35-54 岁女性检测更多病变,HPV 检测伴细胞学分流可平衡 55-64 岁女性的 CIN2+检出率和阴道镜检查数量。需要包括患病率和发病率筛查轮次的纵向数据来评估年龄特异性分流策略。